Journal
Lancet Microbe
Publication Date
6-1-2022
Volume
3
Issue
6
First Page
e435
Last Page
e442
Document Type
Open Access Publication
DOI
10.1016/S2666-5247(22)00043-X
Rights and Permissions
Armstrong E, Hemmerling A, Miller S, Burke KE, Newmann SJ, Morris SR, Reno H, Huibner S, Kulikova M, Nagelkerke N, Coburn B, Cohen CR, Kaul R. Sustained effect of LACTIN-V (Lactobacillus crispatus CTV-05) on genital immunology following standard bacterial vaginosis treatment: results from a randomised, placebo-controlled trial. Lancet Microbe. 2022 Jun;3(6):e435-e442. doi: 10.1016/S2666-5247(22)00043-X. © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Recommended Citation
Armstrong, Eric; Hemmerling, Anke; Miller, Steve; Burke, Kerianne E.; Newmann, Sara J.; Morris, Sheldon R.; Reno, Hilary; Huibner, Sanja; Kulikova, Maria; Nagelkerke, Nico; Coburn, Bryan; Cohen, Craig R.; and Kaul, Rupert, "Sustained effect of LACTIN-V (Lactobacillus crispatus CTV-05) on genital immunology following standard bacterial vaginosis treatment: Results from a randomised, placebo-controlled trial." Lancet Microbe. 3, 6. e435 - e442. (2022).
https://digitalcommons.wustl.edu/oa_4/1627
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
Correction